Logo image of DMAC

DIAMEDICA THERAPEUTICS INC (DMAC) Stock Fundamental Analysis

NASDAQ:DMAC - Nasdaq - CA25253X2077 - Common Stock - Currency: USD

4.2  +0.08 (+1.94%)

After market: 4.2 0 (0%)

Fundamental Rating

2

Overall DMAC gets a fundamental rating of 2 out of 10. We evaluated DMAC against 558 industry peers in the Biotechnology industry. While DMAC seems to be doing ok healthwise, there are quite some concerns on its profitability. DMAC does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year DMAC has reported negative net income.
DMAC had a negative operating cash flow in the past year.
DMAC had negative earnings in each of the past 5 years.
DMAC had a negative operating cash flow in each of the past 5 years.
DMAC Yearly Net Income VS EBIT VS OCF VS FCFDMAC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M -25M

1.2 Ratios

DMAC's Return On Assets of -69.53% is on the low side compared to the rest of the industry. DMAC is outperformed by 63.98% of its industry peers.
DMAC's Return On Equity of -79.52% is in line compared to the rest of the industry. DMAC outperforms 51.08% of its industry peers.
Industry RankSector Rank
ROA -69.53%
ROE -79.52%
ROIC N/A
ROA(3y)-42.76%
ROA(5y)-40.38%
ROE(3y)-46.99%
ROE(5y)-43.82%
ROIC(3y)N/A
ROIC(5y)N/A
DMAC Yearly ROA, ROE, ROICDMAC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for DMAC so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
DMAC Yearly Profit, Operating, Gross MarginsDMAC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600 -800 -1K

More info and screens

5

2. Health

2.1 Basic Checks

Compared to 1 year ago, DMAC has more shares outstanding
Compared to 5 years ago, DMAC has more shares outstanding
The debt/assets ratio for DMAC is higher compared to a year ago.
DMAC Yearly Shares OutstandingDMAC Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
DMAC Yearly Total Debt VS Total AssetsDMAC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

2.2 Solvency

DMAC has an Altman-Z score of 14.95. This indicates that DMAC is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 14.95, DMAC belongs to the top of the industry, outperforming 91.40% of the companies in the same industry.
DMAC has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
DMAC has a Debt to Equity ratio (0.00) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 14.95
ROIC/WACCN/A
WACCN/A
DMAC Yearly LT Debt VS Equity VS FCFDMAC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M

2.3 Liquidity

A Current Ratio of 8.02 indicates that DMAC has no problem at all paying its short term obligations.
With a decent Current ratio value of 8.02, DMAC is doing good in the industry, outperforming 70.25% of the companies in the same industry.
DMAC has a Quick Ratio of 8.02. This indicates that DMAC is financially healthy and has no problem in meeting its short term obligations.
With a decent Quick ratio value of 8.02, DMAC is doing good in the industry, outperforming 70.43% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 8.02
Quick Ratio 8.02
DMAC Yearly Current Assets VS Current LiabilitesDMAC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for DMAC have decreased strongly by -14.29% in the last year.
EPS 1Y (TTM)-14.29%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-28.57%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

DMAC is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 16.02% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-32.03%
EPS Next 2Y-16.38%
EPS Next 3Y-14.8%
EPS Next 5Y16.02%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
DMAC Yearly Revenue VS EstimatesDMAC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2027 2028 2029 2030 2031 2032 50M 100M 150M
DMAC Yearly EPS VS EstimatesDMAC Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 0.5 -0.5 1

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

DMAC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year DMAC is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
DMAC Price Earnings VS Forward Price EarningsDMAC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
DMAC Per share dataDMAC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5

4.3 Compensation for Growth

A cheap valuation may be justified as DMAC's earnings are expected to decrease with -14.80% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-16.38%
EPS Next 3Y-14.8%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for DMAC!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

DIAMEDICA THERAPEUTICS INC

NASDAQ:DMAC (6/4/2025, 8:20:13 PM)

After market: 4.2 0 (0%)

4.2

+0.08 (+1.94%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-13 2025-05-13/amc
Earnings (Next)08-05 2025-08-05/amc
Inst Owners17.54%
Inst Owner Change11.64%
Ins Owners13.97%
Ins Owner Change5.8%
Market Cap180.10M
Analysts84
Price Target10.71 (155%)
Short Float %2.8%
Short Ratio8.63
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.17%
Min EPS beat(2)-2.3%
Max EPS beat(2)1.96%
EPS beat(4)3
Avg EPS beat(4)5.86%
Min EPS beat(4)-2.3%
Max EPS beat(4)18.65%
EPS beat(8)7
Avg EPS beat(8)7.02%
EPS beat(12)10
Avg EPS beat(12)7.08%
EPS beat(16)14
Avg EPS beat(16)13.34%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)31.25%
EPS NQ rev (1m)-3.64%
EPS NQ rev (3m)9.52%
EPS NY rev (1m)-1.75%
EPS NY rev (3m)1.69%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 5.3
P/tB 5.3
EV/EBITDA N/A
EPS(TTM)-0.64
EYN/A
EPS(NY)-0.81
Fwd EYN/A
FCF(TTM)-0.53
FCFYN/A
OCF(TTM)-0.53
OCFYN/A
SpS0
BVpS0.79
TBVpS0.79
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -69.53%
ROE -79.52%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-42.76%
ROA(5y)-40.38%
ROE(3y)-46.99%
ROE(5y)-43.82%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 66.67%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.02
Quick Ratio 8.02
Altman-Z 14.95
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)156.03%
Cap/Depr(5y)156.72%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-14.29%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-28.57%
EPS Next Y-32.03%
EPS Next 2Y-16.38%
EPS Next 3Y-14.8%
EPS Next 5Y16.02%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-35.36%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-52.97%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-76.56%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-77.56%
OCF growth 3YN/A
OCF growth 5YN/A